Coherus BioSciences (CHRS) News Today → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free CHRS Stock Alerts $2.02 -0.16 (-7.34%) (As of 04/24/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineCoherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meetingglobenewswire.com - April 24 at 10:02 AMShort Interest in Coherus BioSciences, Inc. (NASDAQ:CHRS) Declines By 9.5%marketbeat.com - April 15 at 11:56 AMInvestors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 83% over the last five yearsfinance.yahoo.com - April 11 at 8:35 AMVanguard Group Inc. Purchases 932,476 Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS)marketbeat.com - April 11 at 4:11 AMCoherus BioSciences, Inc. (NASDAQ:CHRS) Given Average Recommendation of "Moderate Buy" by Brokeragesmarketbeat.com - April 11 at 2:29 AMCoherus BioSciences, Inc.: Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meetingfinanznachrichten.de - April 8 at 3:14 PMCoherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meetingglobenewswire.com - April 8 at 8:30 AMCoherus BioSciences, Inc. (NASDAQ:CHRS) Short Interest Up 7.1% in Marchmarketbeat.com - April 2 at 7:16 AMCoherus Biosciences: Dumping One Drug But Showing Promise With Anotherseekingalpha.com - March 21 at 12:02 AMCoherus BioSciences (NASDAQ:CHRS) PT Lowered to $11.00marketbeat.com - March 20 at 8:22 AMCoherus BioSciences (NASDAQ:CHRS) Earns "Buy" Rating from HC Wainwrightmarketbeat.com - March 18 at 4:34 PMCoherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 16 at 4:08 PMAnalysts Offer Insights on Healthcare Companies: Coherus Biosciences (CHRS) and Solid Biosciences (SLDB)markets.businessinsider.com - March 15 at 8:08 AMCoherus Biosciences: Strong Q4 Performance and Strategic Moves Merit Outperform Ratingmarkets.businessinsider.com - March 15 at 8:08 AMCoherus BioSciences Full Year 2023 Earnings: EPS Misses Expectationsfinance.yahoo.com - March 15 at 8:08 AMWhy Coherus Biosciences Stock Tumbled on Thursdayfool.com - March 14 at 6:28 PMCoherus BioSciences, Inc. (CHRS) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 14 at 3:43 PMQ4 2023 Coherus BioSciences Inc Earnings Callfinance.yahoo.com - March 14 at 10:42 AMRecap: Coherus BioSciences Q4 Earningsbenzinga.com - March 13 at 6:26 PMCoherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Updatemarkets.businessinsider.com - March 13 at 6:26 PMCoherus BioSciences Non-GAAP EPS of -$0.62 misses by $0.52, revenue of $91.5M beats by $1.07Mmsn.com - March 13 at 6:26 PMCoherus BioSciences Inc (CHRS) Reports Growth in Net Revenue for Q4 and Full Year 2023 Despite ...finance.yahoo.com - March 13 at 6:26 PMCoherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Updateglobenewswire.com - March 13 at 4:01 PMCoherus BioSciences Q4 2023 Earnings Previewmsn.com - March 12 at 5:53 PMIn the wake of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) latest US$49m market cap drop, institutional owners may be forced to take severe actionsfinance.yahoo.com - March 6 at 4:17 PMCoherus BioSciences (CHRS) to Release Quarterly Earnings on Wednesdaymarketbeat.com - March 6 at 9:14 AMCoherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024globenewswire.com - March 5 at 4:01 PMCoherus BioSciences, Inc.: Coherus Completes Divestiture of Ophthalmology Franchisefinanznachrichten.de - March 4 at 9:46 AMCoherus Completes Divestiture of Ophthalmology Franchiseglobenewswire.com - March 4 at 1:00 AMCoherus BioSciences (CHRS) Set to Announce Quarterly Earnings on Mondaymarketbeat.com - March 3 at 7:31 AMBrandywine Global Investment Management LLC Boosts Stake in Coherus BioSciences, Inc. (NASDAQ:CHRS)marketbeat.com - February 25 at 6:24 AMCoherus BioSciences Announces New Employment Inducement Grantsglobenewswire.com - February 23 at 5:33 PMCoherus BioSciences Stock (NASDAQ:CHRS), Short Interest Reportbenzinga.com - February 21 at 10:29 PMCoherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqvfinance.yahoo.com - February 21 at 12:29 PMCoherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqvglobenewswire.com - February 21 at 8:30 AMRafferty Asset Management LLC Takes Position in Coherus BioSciences, Inc. (NASDAQ:CHRS)marketbeat.com - February 21 at 6:43 AMPrincipal Financial Group Inc. Sells 369,858 Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS)marketbeat.com - February 16 at 4:14 AMBarclays PLC Has $8.88 Million Stock Position in Coherus BioSciences, Inc. (NASDAQ:CHRS)marketbeat.com - February 8 at 5:38 AMCoherus BioSciences Inc (CHRS)investing.com - February 7 at 10:16 AMCoherus Biosciences Amends Loan Terms with Biopharmamarkets.businessinsider.com - February 6 at 10:49 AMCoherus Biosciences Announces Key Consent and Amendmentmsn.com - February 6 at 10:49 AMCoherus Amends Term Loan Agreement with Pharmakon Advisors, LPfinance.yahoo.com - February 5 at 8:17 AMCoherus BioSciences, Inc. (NASDAQ:CHRS) Given Consensus Recommendation of "Moderate Buy" by Brokeragesmarketbeat.com - January 27 at 2:52 AMAnalysts Are More Bearish On Coherus BioSciences, Inc. (NASDAQ:CHRS) Than They Used To Befinance.yahoo.com - January 25 at 9:39 AMCoherus BioSciences (NASDAQ:CHRS) PT Lowered to $9.00marketbeat.com - January 23 at 3:43 PMWhy Coherus BioSciences Stock Is Sinking Todayfool.com - January 23 at 12:36 PMPeninsula drugmaker divests biosimilar eye drug for $170M cashbizjournals.com - January 22 at 3:19 PMWhy Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today?msn.com - January 22 at 3:19 PMCoherus (NASDAQ:CHRS) Surges After $170M Deal with Sandoz for CIMERLI Franchisemsn.com - January 22 at 3:19 PMCoherus Shares Rise Premarket on Sale of Ophthalmology Franchisemarketwatch.com - January 22 at 10:18 AM Get Coherus BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address The Hard Truth About Investing For Retirement (Ad)Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading. Click To Access This Powerful Training Right Now! CHRS Media Mentions By Week CHRS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CHRS News Sentiment▼0.000.43▲Average Medical News Sentiment CHRS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CHRS Articles This Week▼13▲CHRS Articles Average Week Get Coherus BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Adverum Biotechnologies News Sutro Biopharma News X4 Pharmaceuticals News Compass Therapeutics News Elevation Oncology News Acumen Pharmaceuticals News Innate Pharma News Opthea News Fennec Pharmaceuticals News Black Diamond Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CHRS) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsFed launches fourth dollar overhaulStansberry ResearchThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
